Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: December 30, 2011
Last updated: November 2, 2013
Last verified: November 2013
The purpose of this study is to confirm the efficacy of triple therapy with TAK-438, Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to triple therapy with Lansoprazole, Amoxicillin and Clarithromycin in H. pylori-positive patients with scarred gastric or duodenal ulcers.

Condition Intervention Phase
H. Pylori Infection
Drug: TAK-438
Drug: Lansoprazole
Drug: Amoxicillin
Drug: Clarithromycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the First Line Eradication of H.Pylori

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • H. pylori eradication rate 4 weeks after completion of first-line therapy [ Time Frame: 4-weeks post-dose (first-line therapy) ]
    The participants are judged to be H. pylori-negative or H. pylori-positive based on the 13C-Urea Breath Test.

Secondary Outcome Measures:
  • H. pylori eradication rate 4 weeks after completion of second-line therapy [ Time Frame: 4-weeks post-dose (second-line therapy) ]

Enrollment: 650
Study Start Date: January 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAK-438 20 mg BID

TAK-438 20 mg, tablets, orally, twice daily for 1 week

Lansoprazole placebo-matching capsules, orally, twice daily for 1 week

Amoxicillin 750 mg, capsules, orally, twice daily for 1 week

Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week

Drug: TAK-438 Drug: Amoxicillin Drug: Clarithromycin
Experimental: Lansoprazole 30 mg BID

TAK-438 placebo-matching tablets, orally, twice daily for 1 week

Lansoprazole 30 mg, capsules, orally, twice daily for 1 week

Amoxicillin 750 mg, capsules, orally, twice daily for 1 week

Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week

Drug: Lansoprazole
Other Name: AG-1749
Drug: Amoxicillin Drug: Clarithromycin


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participants must be H. pylori-positive patients at baseline (Visit 1)
  2. Participants must be endoscopically confirmed to have scarred gastric ulcer or duodenal ulcer at baseline (Visit 1).

    However, if a history of ulcers is confirmed by the medical interview or previous medical record, Participants whose gastric ulcer scar or duodenal ulcer scar has disappeared may be included in the study.

  3. Outpatient (including inpatient for examination)

Exclusion Criteria:

  1. Participants who have received H.pylori eradication treatment
  2. Participants who have either acute upper gastrointestinal bleeding, gastric ulcer [mucosal defect (with white coating including clot adherence) of 3 mm or larger in size], duodenal ulcer [mucosal defect (with white coating including clot adherence) of 3 mm or larger in size], acute gastric mucosal lesion (AGML), or acute duodenal mucosal lesion (ADML) on endoscopic examination at baseline (Visit 1).

    However, participants with gastric erosion or duodenal erosion may be included in the study.

  3. Participants who have received or who are scheduled to undergo surgery which affects gastric acid secretion (ex, resection of upper gastrointestinal tract, vagotomy, etc)
  4. Participants who cannot be treated with medicinal treatment (ex, perforation, pyloric stenosis or large hemorrhage, etc)
  5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
  6. Participants with hepatic or renal impairment receiving treatment with colchicines
  7. Participants who have a history of hypersensitivity or allergy to TAK-438 (including its excipients), PPIs, penicillin antibiotics, macrolide antibiotics, or antitrichomonal agents
  8. Participants with infectious mononucleosis
  9. Participants with an organic disease of the brain or spinal cord
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01505127

Abiko-shi, Chiba, Japan
Kashiwa-shi, Chiba, Japan
Fukui-shi, Fukui, Japan
Fukuoka-shi, Fukuoka, Japan
Ishikari-shi, Hokkaido, Japan
Sapporo-shi, Hokkaido, Japan
Kobe-shi, Hyogo, Japan
Nishinomiya-shi, Hyogo, Japan
Marugame-shi, Kagawa, Japan
Takamatsu-shi, Kagawa, Japan
Kagoshima-shi, Kagoshima, Japan
Ebina-shi, Kanagawa, Japan
Yokohama-shi, Kanagawa, Japan
Yatsushiro-shi, Kumamoto, Japan
Kyoto-shi, Kyoto, Japan
Oita-shi, Oita, Japan
Hirakata-shi, Osaka, Japan
Osaka-shi, Osaka, Japan
Sakai-shi, Osaka, Japan
Suita-shi, Osaka, Japan
Takatsuki-shi, Osaka, Japan
Toyonaka-shi, Osaka, Japan
Saga-shi, Saga, Japan
Kumagaya-shi, Saitama, Japan
Tokorozawa-shi, Saitama, Japan
Shizuoka-shi, Shizuoka, Japan
Adachi-ku, Tokyo, Japan
Chiyoda-ku, Tokyo, Japan
Hachioji-shi, Tokyo, Japan
Kokubunji-shi, Tokyo, Japan
Nishi-tokyo-shi, Tokyo, Japan
Oota-ku, Tokyo, Japan
Ota-ku, Tokyo, Japan
Setagaya-ku, Tokyo, Japan
Shibuya-ku, Tokyo, Japan
Sponsors and Collaborators
Study Director: Senior Manager Takeda
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Takeda Identifier: NCT01505127     History of Changes
Other Study ID Numbers: TAK-438/CCT-401
U1111-1126-5073 ( Registry Identifier: WHO )
JapicCTI-111722 ( Registry Identifier: JapicCTI )
Study First Received: December 30, 2011
Last Updated: November 2, 2013

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors processed this record on May 25, 2017